Relevant bibliographies by topics / Glioma diagnosis

Academic literature on the topic 'Glioma diagnosis'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Glioma diagnosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Glioma diagnosis"

1

Cherkasova, Olga, Yan Peng, Maria Konnikova, Yuri Kistenev, Chenjun Shi, Denis Vrazhnov, Oleg Shevelev, Evgeny Zavjalov, Sergei Kuznetsov, and Alexander Shkurinov. "Diagnosis of Glioma Molecular Markers by Terahertz Technologies." Photonics 8, no. 1 (January 16, 2021): 22. http://dx.doi.org/10.3390/photonics8010022.

Full text
Abstract:
This review considers glioma molecular markers in brain tissues and body fluids, shows the pathways of their formation, and describes traditional methods of analysis. The most important optical properties of glioma markers in the terahertz (THz) frequency range are also presented. New metamaterial-based technologies for molecular marker detection at THz frequencies are discussed. A variety of machine learning methods, which allow the marker detection sensitivity and differentiation of healthy and tumor tissues to be improved with the aid of THz tools, are considered. The actual results on the application of THz techniques in the intraoperative diagnosis of brain gliomas are shown. THz technologies’ potential in molecular marker detection and defining the boundaries of the glioma’s tissue is discussed.
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, Ian, Lisa Scarpace, Rachel Hunt, Kevin Nelson, Darshana Patil, Vineet Datta, Dadasaheb Akolkar, et al. "PATH-64. PROSPECTIVE, BLINDED PLASMA BASED ANALYSIS FOR DIAGNOSIS OF NEWLY DIAGNOSED GLIOMA." Neuro-Oncology 21, Supplement_6 (November 2019): vi157—vi158. http://dx.doi.org/10.1093/neuonc/noz175.659.

Full text
Abstract:
Abstract INTRODUCTION In patients with newly diagnosed intracerebral lesions, gliomas are often suspected. However, other conditions such as multiple sclerosis, abscess or lymphoma are possible, as well. Furthermore, biopsy can be challenging due to eloquent and/or deep location within the brain. In this prospective, blinded study, analysis of plasma isolated cell-free DNA and exosome mRNA and miRNA from newly diagnosed glioma patients and from cancer-free volunteers was used to predict disease. METHODS Plasma was drawn from 52 patients with newly diagnosed gliomas (28 high grade glioma (HGG), 10 low grade (LGG)) and 14 patients without documented history of cancer and recent MRI brain which was negative for brain tumor. High quality DNA and RNA was isolated and sequenced using Next Generation Sequencing and Digital Droplet PCR was used for detection and verification of trace molecular artifacts. Multianalyte processing yielded data that was harmonized and interpreted through an Artificial Intelligence based algorithm to assess for possible glioma and to assign grade in a blinded fashion. EGFRvIII, TP53 and IDH1 mutations were also analyzed and compared to molecular testing from tumor specimens. RESULTS 66% (25 of 38) of glioma patients were correctly diagnosed as having a malignancy. 43% of HGG and 60% of LGG patients were correctly graded. Of the 14 normal controls, 6 were concluded to be cancer-free. IDH1, EGFRvIII, and TP53 mutation had concordance of 64% (21/33), 82% (14/17) and 36% (5/14), respectively. CONCLUSIONS Analysis of plasma cell free tumor derived DNA and RNA was relatively sensitive for detecting glioma in treatment naïve patients. In contrast, this analysis was not specific in ruling out malignancy in the normal control patients. Given this profile, in patients with newly diagnosed intracerebral lesions suspicious for glioma, this may be a useful screening test to determine the need for more invasive testing, i.e. biopsy/resection.
APA, Harvard, Vancouver, ISO, and other styles
3

Nechipay, E. A., M. B. Dolgushin, A. I. Pronin, E. A. Kobyakova, and L. M. Fadeeva. "Dynamic Contrast Enhanced MRI in Glioma Diagnosis." Medical Visualization, no. 4 (August 28, 2017): 88–96. http://dx.doi.org/10.24835/1607-0763-2017-4-88-96.

Full text
Abstract:
The aim: to examine the possibility of using dynamic contrast enhanced magnetic resonance imaging (DCE MRI) in clarifying the diagnosis of glial brain tumors and the differentiation between them on the basis of the malignancy degree. In this regard, the authors evaluated the effectiveness of perfusion parameters (Ktrans, Kep, Ve and iAUC).Materials and methods.The study included examination of 54 patients with an established presence of brain glial tumors. Glioma Grade I–II diagnosed in 13 (24.1%) and glioma Grade III–IV in 41 (75.9%) cases. Morphological verification of the diagnosis obtained as a result of either surgical removal of the tumor or stereotactic biopsy was achieved in 31 (57.4%) patients: glial tumors Grade I–II identified in 6 (19.4%), and glioma Grade III–IV – 25 (80.6%) cases. Results. According to DCE increasing of the malignancy degree of glial tumors is followed by increasing of all perfusion parameters: thus, the lowest values of Ktrans, Kep, Ve and iAUC were identified in low grade gliomas (0.026 min−1, 0.845 min−1, 0.024 and 1.757, respectively), the highest in gliomas Grade III–IV (0.052 min−1 1.083 min−1, 0.06 and 2.694, respectively). The most informative parameters with sensi tivity 90% and specificity 100% in the differential diagnosis of gliomas Grade I-II and Grade III-IV are Ktrans (cut-off = 0.16 min−1) and Ve (cut-off = 0.13).Conclusion.DCE MRI can be used in differential diagnosis of glial brain tumors of different malignancy grade.
APA, Harvard, Vancouver, ISO, and other styles
4

Zhao, Shiguang. "BIOM-63. DIAGNOSIS AND PROGNOSTIC SIGNIFICANCE OF CIRCULATING miR-2276-5p IN PLASMA OF GLIOMA PATIENTS." Neuro-Oncology 22, Supplement_2 (November 2020): ii15. http://dx.doi.org/10.1093/neuonc/noaa215.060.

Full text
Abstract:
Abstract Circulating microRNAs (miRNAs) in plasma have the potential to become diagnostic and prognostic biomarkers for various cancers. This study hopes to use plasma circulating miRNAs as biomarkers for diagnosis and prognosis of glioma patients. METHOD: In this study, the plasma circulating miRNAs of 124 patients with glioma and 36 controls was collected to detect the relative expression of miR-2276-5p, and the specificity and sensitivity of the diagnosis were verified by ROC curve. The follow-up survival status was analyzed by cox regression analysis. RESULT: In the GSE 139031 database, it was found that the expression of circulating miR-2276-5p in plasma of glioma patients was significantly lower than that of patients with non-gliomas. Using our plasma samples, and it is indicated that the expression of circulating miR-2276-5p in plasma is lower than that of healthy patients, and compared with low-grade gliomas, patients with high-grade gliomas have a lower expression of circulating miR-2276-5p. ROC curve analysis found that the AUC value was 0.851. The low expression of circulating miR-2276-5p in plasma of glioma patients indicates a poor prognosis of glioma patients, After univariate and multifactorial cox regression analysis, which can be used as an independent prognostic risk factor for glioma patients (P< 0.05). CONCLUSION: The expression of circulating miR-2276-5p in plasma of glioma patients was significantly lower than that of the control group, compared with low-grade gliomas, patients with high-grade gliomas have a lower expression of circulating miR-2276-5p. The lower the relative expression of circulating miR-2276-5p indicated that glioma patients had a worse prognosis.
APA, Harvard, Vancouver, ISO, and other styles
5

Yin, Luxin, and Liwei Zhang. "Correlation Between MRI Findings and Histological Diagnosis of Brainstem Glioma." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 40, no. 3 (May 2013): 348–54. http://dx.doi.org/10.1017/s0317167100014293.

Full text
Abstract:
Objective:In most studies, treatment decisions of brainstem glioma are based solely on MRI features and do not incorporate a histopathological diagnosis. In the current study, we sought to compare MRI characteristics with histopathological findings of bainstem glioma.Methods:From April 2003 through April 2012, 150 patients were diagnosed with brainstem gliomas by MRI and microsurgically treated in Tiantan Hospital, Beijing, China. All the MRI and histopathological findings of these patients were respectively reviewed.Results:Of the 150 patients, 65 were female and 85 were male, 120 were adults and 30 were children (age < 18 years), 108 were low-grade glioma (72.0%), 35 were high-grade glioma (23.3%). The accuracy of the MRI diagnosis for brainstem glioma was 95.3%. Data analysis of the MRI findings revealed that a focal lesion was associated with a more favorable histopathological diagnosis in intrinsic (P=0.005) and exophytic (P=0.001) brainstem glioma patients. In the intrinsic diffuse type, tumors without enhancement had more favorable pathological findings (P=0.009).Conclusions:To our knowledge, this is the largest case series of this nature reported in the literature to date. The results of this study suggest that MRI features of brainstem gliomas could predict some pathological features and guide prognosis, choice of biopsy and treatment modalities. The pathology of tumors with a focal appearance on MRI was associated with a prognosis that was significantly better than their diffuse counterparts. For the intrinsic diffuse gliomas, non-enhancing tumors had pathology suggestive of a favorable prognosis.
APA, Harvard, Vancouver, ISO, and other styles
6

Du, Peng, Hongyi Chen, Kun Lv, and Daoying Geng. "A Survey of Radiomics in Precision Diagnosis and Treatment of Adult Gliomas." Journal of Clinical Medicine 11, no. 13 (June 30, 2022): 3802. http://dx.doi.org/10.3390/jcm11133802.

Full text
Abstract:
Glioma is the most common primary malignant tumor of the adult central nervous system (CNS), which mostly shows invasive growth. In most cases, surgery is often difficult to completely remove, and the recurrence rate and mortality of patients are high. With the continuous development of molecular genetics and the great progress of molecular biology technology, more and more molecular biomarkers have been proved to have important guiding significance in the individualized diagnosis, treatment, and prognosis evaluation of glioma. With the updates of the World Health Organization (WHO) classification of tumors of the CNS in 2021, the diagnosis and treatment of glioma has entered the era of precision medicine in the true sense. Due to its ability to non-invasively achieve accurate identification of glioma from other intracranial tumors, and to predict the grade, genotyping, treatment response, and prognosis of glioma, which provides a scientific basis for the clinical application of individualized diagnosis and treatment model of glioma, radiomics has become a research hotspot in the field of precision medicine. This paper reviewed the research related to radiomics of adult gliomas published in recent years and summarized the research proceedings of radiomics in differential diagnosis, preoperative grading and genotyping, treatment and efficacy evaluation, and survival prediction of adult gliomas.
APA, Harvard, Vancouver, ISO, and other styles
7

Ogawa, Tomoya, Keisuke Miyake, Takeshi Fujimori, Daisuke Ogawa, Masaki Okada, Tetsuhiro Hatakeyama, Masanobu Okauchi, Atsushi Shindo, Masahiko Kawanishi, and Takashi Tamiya. "NI-15 THE USEFULNESS OF PET IMAGING IN MOLECULAR DIAGNOSIS OF GLIOMA." Neuro-Oncology Advances 1, Supplement_2 (December 2019): ii28. http://dx.doi.org/10.1093/noajnl/vdz039.127.

Full text
Abstract:
Abstract OBJECTIVE After WHO 2016 Classification of Tumors of the Central Nervous System have published, molecular diagnosis became part of the diagnostic criteria. In this study, we investigated the correlation between PET images and molecular diagnosis of glioma. METHODS We performed retrospective review of newly diagnosed supratentorial glioma patients who preoperatively underwent all four PET examinations (18F-FDG, 11C-MET, 18F-FLT and 18F-FMISO) from April 2009 to March 2019. The standardized uptake value (SUV) from the accumulation of each PET tracers, TNR (tumor to contralateral normal tissue ratio) of 18F-FDG,11C-MET and 18F-FLT, TBR (tumor to blood values ratio) of 18F-FMISO were measured. We investigated the correlation between these PET images and molecular diagnosis of glioma. RESULTS Data from total of 79 patients which were 42 cases of IDH wild type glioblastoma, 2 cases of IDH mutated glioblastoma, 9 cases of IDH wild type astrocytoma, 13 cases of IDH mutated astrocytoma and 13 cases of IDH mutated and 1p/19q co-deleted oligodendroglioma were included in this study. Both TNR of 11C-MET(p&lt;0.01) and 18F-FLT(p&lt;0.01), and also TBR of 18F-FMISO(p&lt;0.01) in IDH wild type gliomas showed significantly higher than IDH mutated gliomas. In WHO Gr2-3 gliomas, only TNR of 18F-FLT showed a significant difference between IDH wild type gliomas and IDH mutated gliomas(p&lt;0.01). TNR of 18F-FLT(p&lt;0.01) and TBR of 18F-FMISO(p&lt;0.01) in 1p/19q co-deleted gliomas were significantly lower than gliomas without 1p/19q co-deletion, but there were no significant differences in WHO Gr2-3 gliomas. Among IDH mutated gliomas, TNR of 11C-MET in 1p/19q co-deleted gliomas showed significantly higher uptake than gliomas without 1p/19q co-deletion(p&lt;0.05). CONCLUSION Preoperative PET evaluation of each PET tracers may be useful for the molecular diagnosis of glioma.
APA, Harvard, Vancouver, ISO, and other styles
8

Cheng, Chuandong, Ying Ji, Tiantian Han, Xiaomin Li, Yahui Huang, Weijie Sun, Guanghua Lu, Wanglong Deng, Ran Ding, and Fanfeng Bu. "MAPK pathway alteration may be a new integrated diagnosis term." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e14022-e14022. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14022.

Full text
Abstract:
e14022 Background: The 2016 CNS WHO classification is the first to include molecular factors to classify in glioma. We are in the age of glioma subgroups, in which the category depended on the histological and molecular composition, providing more clinical behavior, prognosis, and therapeutic targets hints. The most well-known molecular modifications are IDH1/2 mutation, ATRX variant, TP53 variant, BRAF mutation or fusion, 1p/19q co-deletions. However, there is a diagnostic term“NOS” in the 2016 CNS WHO classification，which indicates that a tumor could not be placed into a more specific WHO category. Here, our analysis of the MAPK pathway may suggest a new subtype. Methods: Targeted next-generation DNA sequence of the 131-genes panel was performed on gliomas in 119 patients. We measured the somatic variations in the MAPK pathway after filtering known driver mutations. The analysis of genomic alterations was performed using a two-sided Fisher exact test. Results: 90/119（75.6%）were excluded due to known driver mutations. 29/119(24.4%) were classified in NOS with a typical “single MAPK pathway alteration” and different histological characteristics and WHO grade. The median age at diagnosis was 35 years (4-79) in our gliomas. The most frequent mutations were NF1(10/29), FGFR1(7/29), KRAS (6/29), BRAF (3/29), PTPN11(2/29), although there are other gene mutations like FGFR2, FGFR3, AKT1, MAP2K1. According to cIMPACT-NOW update 4, our pediatric gliomas ( < 30 years, n = 14) could be identified as “diffuse glioma, other MAPK pathway alteration.” Our adult gliomas have a higher frequency of NF1 mutations（8/15 vs. 2/14, p = 0.05), a lower KRAS (1/15 vs. 5/14) and FGFR1 (2/15 vs. 5/14) mutations than children. Conclusions: Our result suggests that MAPK pathway alteration may be a new integrated diagnosis term in all ages of glioma. Moreover, KRAS and FGFR1 may be associated with pediatric gliomas. NF1 is more common in adult gliomas.
APA, Harvard, Vancouver, ISO, and other styles
9

Galijasevic, Malik, Ruth Steiger, Stephanie Mangesius, Julian Mangesius, Johannes Kerschbaumer, Christian Franz Freyschlag, Nadja Gruber, Tanja Janjic, Elke Ruth Gizewski, and Astrid Ellen Grams. "Magnetic Resonance Spectroscopy in Diagnosis and Follow-Up of Gliomas: State-of-the-Art." Cancers 14, no. 13 (June 29, 2022): 3197. http://dx.doi.org/10.3390/cancers14133197.

Full text
Abstract:
Preoperative grade prediction is important in diagnostics of glioma. Even more important can be follow-up after chemotherapy and radiotherapy of high grade gliomas. In this review we provide an overview of MR-spectroscopy (MRS), technical aspects, and different clinical scenarios in the diagnostics and follow-up of gliomas in pediatric and adult populations. Furthermore, we provide a recap of the current research utility and possible future strategies regarding proton- and phosphorous-MRS in glioma research.
APA, Harvard, Vancouver, ISO, and other styles
10

Chaudhary, Reeta, Nishi Tandon, Andleeb Zehra, Jyoti Jaiswal, Nirupma Lal, and Bandhul Tiwari. "HIGH GRADE GLIOMA IN A 2 1/2 YEAR OLD: A CASE REPORT." Era's Journal of Medical Research 9, no. 1 (June 2022): 114–16. http://dx.doi.org/10.24041/ejmr2022.18.

Full text
Abstract:
Gliomas are the tumor of glial cells found in Central nervous System. High Grade Gliomas are rare in pediatric age group. Definitive diagnosis is made by histopathological examination. A 2 ½ year old male admitted with the complaint of abnormal tonic-clonic body movements along with headache, nausea, vomiting and fever. CT scan showed a poorly circumscribed hypodense lesion involving frontoparietal region. Surgery was performed and specimen sent for histopathological examination. Histopathological examination showed mfeatures of high grade glioma like microvascular proliferation, necrosis and haemorrhage. Cerebral tumors are the most common childhood neoplastic tumors. Gliomas are generally classified into low grade glioma and high grade glioma. High Grade glioma is rare in pediatric age group. Most commonly they present in supra tentorial compartment. The most common cerebral cortex involved are frontal lobe followed by parietal and temporal. Clinical signs and symptoms of High grade gliomas are seizure, headache, nausea, vomiting and visual disturbances. CT scan showed a poorly circumscribed hypodense lesion involving left frontoparietal region mainly. Definitive diagnosis of high grade glioma is by histopathological examination. Histopathological examination showed hypercellular heterogeneous tumor lying on a fibrillary background. Areas of microvascular proliferation along with necrosis and haemorrhage are also seen. Surgical resection followed by chemotherapy and local radiotherapy are the present recommendation. High grade gliomas are rare pediatric tumor associated with poor outcome. Surgery was performed due to neurological worsening, which was unsuccessful and patient died. Diagnosis was confirmed on histopathological examination. Poor prognosis and high morbidity even after evolution of treatment, demands further research to improve the prognosis and reduce morbidities.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Glioma diagnosis"

1

Marand, Sandie. "Identification et caractérisation fonctionnelle de protéines d'intérêt pour le diagnostic et la thérapie des tumeurs gliales." Université Joseph Fourier (Grenoble ; 1971-2015), 2009. http://www.theses.fr/2009GRE10043.

Full text
Abstract:
Les gliomes, et particulièrement les glioblastomes, sont, de par leur pronostic défavorable, un véritable problème de santé publique. La difficulté à les classifier correctement et le manque d'efficacité des thérapies anti-cancéreuses reflètent la méconnaissance de ces tumeurs. Afin d'améliorer le diagnostic, et de mieux comprendre le processus conduisant à la formation des gliomes et donc de trouver de nouveaux traitements, nous avons choisi d'étudier l'immuno-réactivité des sérums de patients. Nous avons ainsi pu découvrir une centaine de protéines dont le statut immunitaire change entre la condition normale et celle pathologique. En identifiant et étudiant ces protéines, nous pouvons mettre en lumière certains mécanismes importants pour la cancérogenèse et définir des clibles clés pour la thérapie. Parmi cette centaine de protéines, nous avons étudié l'immuno-réactivité d'une dizaine qui nous ont permis de définir deux types d'antigènes : ceux dont le statut immunitaire change avec l'apparition de la tumeur et ceux dont le statut change selon la sensibilité de la tumeur vis-à-vis des traitements. Nous avons alors choisi 3 de ces protéines pour les analyser plus en détail : eef1a1, crhsp24, mark3. Ces trois natigènes se trouvent être surexprimés dans les gliomes. L'inhibition de leur expression par si RNA induit une baisse de la prolifération des cellules tumorales, indiquant qu'ils sont impliqués dans la régulation de ce mécanisme. Cette fonction essentielle fait de ces protéines de potentielles cibles thérapeutiques. Les premiers tests de vaccination contre mark3 montrent que l'étude de cet antigène est intéressante même si les résultats ne sont pas ceux espérés. Nous montrons ici que des auto-anticorps associés à la présence des tumeurs gliales peuvent être trouvés dans le sérum. Ces anticorps ont clairement un intérêt diagnostique mais peuvent aussi avoir un intérêt pronostique. Leur analyse biologique peut amener à les considérer comme des cibles thérapeutiques potentielles
Gliomas, particulary glioblastoma, are public health problem because of their dark pronostic. Difficulties to classify and lack of anti-tumor therapy efficiency are due to ignorance about these tumors. To improve diagnosis and also to understand the process leading to glioma formation and so to find new treatment, we choose to study patient sera immuno-reactivity. So we discovered about a hundred of proteins which immune status change between normal and pathological condition. Identifying and studying these proteins, we highlight important mechanisms for cancer and define key targets for therapy. Among these proteins, we studied immuno-reactivity to ten which leads us to define two types of antigens : those which immune status changes with tumor appearance and those who change depending on the sensibility to treatment of the tumor. We then choose three of these proteins for detail analysis : eef1a1, crhsp24, mark3. These three antigens are overexpressed in gliomas. Expression inhibition by siRNA induced a diminution of tumoral cell proliferation, indicating that they are implicated in this mechanism regulation. This essential function makes these potential therapeutic targets. First tests of vaccination toward mark3 show that studying this antigen is of particular interest despite results are not those wished. We show here that auto-antibody associated to glioma presence can be found in sera. These antibodies clearly have diagnosis interest but also can have prognostic interest. Their biological analysis could lead to consider them like potential therapeutic targets
APA, Harvard, Vancouver, ISO, and other styles
2

Di, Stefano Anna Luisa. "Molecular markers of gliomas : implications for diagnosis and new target therapies." Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066015.

Full text
Abstract:
Le travail de thèse est dédié à la caractérisation de fusions spécifiques oncogéniques entre les gènes FGFR et TACC dans les gliomes. Nous avons analysé 907 gliomes pour la présence du gène de fusion FGFR3-TACC3. Nous avons montré que les fusions FGFR3-TACC3 ne touchent que les gliomes IDH wild-type (3%), sont mutuellement exclusives avec l'amplification de EGFR et avec la forme tronquée EGFRvIII et inversement, sont associées à l'amplification de CDK4 et de MDM2 et à la délétion du 10q. Les fusions FGFR3-TACC3 sont associées à une expression intense et diffuse de FGFR3 en immunohistochimie (IHC) et l'IHC pour FGFR3 est un marqueur prédictif très sensible de la présence des fusions FGFR3-TACC3. Les patients porteurs d'une fusion FGFR3-TACC3 ont une survie globale significativement plus longue comparés aux patients avec gliome IDH wild-type. Nous avons traité deux patients porteurs d'un gène de fusion FGFR3-TACC3 avec un inhibiteur tyrosine-kinase (TK) spécifique pour FGFR et nous avons observé une stabilisation de maladie et une réponse mineur chez un patient. Dans la deuxième section nous avons optimisé une nouvelle séquence de spectroscopie différentielle-MEGA-PRESS-pour la détection de l'oncometabolite 2-hydroxyglutarate (2 HG) qui s'accumule de manière spécifique dans les gliomes IDH mutés. Nous avons analysé de façon prospective une cohorte de 25 patients avant chirurgie pour probable gliome de grade II et grade III. Nous avons trouvé que la MEGA-PRESS est hautement spécifique (100%) et sensible (80%) dans la prédiction de la présence de la mutation IDH. Son taux est corrélé aux concentrations de 2 HG mesurés sur tissu congelé par spectrométrie de masse (GC-MS/MS)
This work is devoted to the characterization of a specific oncogenic fusion between FGFR and TACC genes in gliomas. Overall, we screened 907 gliomas for FGFR3-TACC3 fusions. We found that FGFR3-TACC3 fusions exclusively affect IDH wild-type gliomas (3%), and are mutually exclusive with the EGFR amplification and the EGFR vIII variant, whereas it co-occurs with CDK4 amplification, MDM2 amplification and 10q loss. FGFR3–TACC3 fusions were associated with strong and homogeneous FGFR3 immunostaining. We show that FGFR3 immunostaining is a sensitive predictor of the presence of FGFR3-TACC3 fusions. FGFR3-TACC3 glioma patients had a longer overall survival than those patients with IDH wild-type glioma. We treated two patients with FGFR3–TACC3 rearrangements with a specific FGFR-TK inhibitor and we observed a clinical improvement in both and a minor response in one patient. In the second section, we developed a non-invasive diagnostic tool by 1H-magnetic resonance spectroscopy in IDH mutant gliomas. We optimized a uniquely different spectroscopy sequence called MEGA-PRESS for the detection of the oncometabolite 2-hydroxyglutarate (2 HG) that specifically accumulates in IDH mutant gliomas. We analysed a prospective cohort of 25 patients before surgery for suspected grade II and grade III gliomas and we assessed specificity and sensitivity, correlation with 2 HG concentrations in the tumor and associations with grade and genomic background. We found that MEGA-PRESS is highly specific (100%) and sensitive (80%) for the prediction of IDH mutation and correlated with 2 HG levels measured by gas chromatography-tandem mass spectrometry (GC-MS/MS) in frozen tissue
APA, Harvard, Vancouver, ISO, and other styles
3

OLIVEIRA, ERICA A. de. "Desenvolvimento de radiotraçadores angiogênicos para diagnóstico de glioma: estudo em modelo animal." reponame:Repositório Institucional do IPEN, 2014. http://repositorio.ipen.br:8080/xmlui/handle/123456789/23233.

Full text
Abstract:
Submitted by Claudinei Pracidelli (cpracide@ipen.br) on 2015-01-07T16:11:01Z No. of bitstreams: 0
Made available in DSpace on 2015-01-07T16:11:01Z (GMT). No. of bitstreams: 0
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Tese (Doutorado em Tecnologia Nuclear)
IPEN/T
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
FAPESP:11/12405-0
APA, Harvard, Vancouver, ISO, and other styles
4

Farias, Alana Alves. "Análise da marcação de células da linhagem C6 de glioma com as lectinas vegetais CPL, WGA e Con A." reponame:Repositório Institucional da FIOCRUZ, 2015. https://www.arca.fiocruz.br/handle/icict/13028.

Full text
Abstract:
Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-03-04T18:04:54Z No. of bitstreams: 1 Alana Alves Farias Análise da marcação...2015.pdf: 1042656 bytes, checksum: 8c570ad74d5f6150c8fb9527f324b2d4 (MD5)
Approved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-03-04T18:05:20Z (GMT) No. of bitstreams: 1 Alana Alves Farias Análise da marcação...2015.pdf: 1042656 bytes, checksum: 8c570ad74d5f6150c8fb9527f324b2d4 (MD5)
Made available in DSpace on 2016-03-04T18:05:20Z (GMT). No. of bitstreams: 1 Alana Alves Farias Análise da marcação...2015.pdf: 1042656 bytes, checksum: 8c570ad74d5f6150c8fb9527f324b2d4 (MD5) Previous issue date: 2015
Fundação Oswaldo Cruz, Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
ntrodução e objetivos: O glioblastoma multiforme é um glioma de alto grau que apresenta um prognóstico ruim. O diagnóstico definitivo é estabelecido pela avaliação histológica, porém este pode apresentar conflitos na classificação, com isso surge à necessidade de ferramentas que auxiliem o patologista em sua análise. Atualmente, maior ênfase tem sido dada a alterações na glicosilação, pois estão associadas a neoplasias, e a descoberta da capacidade de lectinas em reconhecer tais alterações fez destas, ferramentas aplicáveis para o diagnóstico biomédico. Dessa forma, o objetivo deste trabalho é analisar a marcação das lectinas CpL, WGA e Con A em células da linhagem C6 e astrócitos. Métodos: As células foram cultivadas em condições estéreis, a 37ºC em atmosfera com 5 % de CO2 até atingirem confluência. Em seguida, foram lavadas com PBS e marcadas com as lectinas CpL, WGA e Con A numa concentração de 1 mg/ml, o controle negativo foi obtido com adição do carboidrato inibidor das lectinas (D-galactose, β-N-acetilglucosamina e glicose), respectivamente, numa concentração de 0,1 M. A incubação se deu por uma hora com proteção da luz, a análise foi realizada em microscópio de fluorescência. Para a quantificação em citometria de fluxo, as células foram marcadas obedecendo ao mesmo protocolo anterior, com exceção do tempo de incubação que se deu por 15 minutos. Posteriormente, as células foram lavadas, centrifugadas, transferidas para tubos e ressuspensas em PBS para a realização da leitura em citômetro. Resultados: A lectina CpL apresentou melhor marcação para os astrócitos, porém, ainda assim, mostra baixo desempenho comparado com as demais lectinas. Já a lectina WGA apresentou marcação eficiente tanto para astrócitos quanto para as células C6, esta última apresentou o dobro de emissão. Desta forma, é possível inferir que as lectinas CpL e WGA não são capazes de reconhecer diferenças importantes no perfil de glicoconjugados nas membranas das células C6 e dos astrócitos. Entretanto, a lectina Con A revelou marcação eficiente em relação às células C6 capaz de definir a forma celular, mostrando que há uma distribuição quase uniforme destes carboidratos ao longo da superfície da membrana, e ainda exibiu mediana de fluorescência cerca de 99 vezes superior em relação aos astrócitos. Assim, a Con A mostrou ser um marcador capaz de diferenciar as células da linhagem de glioma murino das células de cultura primária. Conclusão: Com base nestes resultados podemos inferir que a lectina Con A pode auxiliar numa identificação mais eficiente com possibilidade de um diagnóstico mais seguro.
Introduction and objectives: Glioblastoma multiforme is a high-grade glioma that has a poor prognosis. The definitive diagnosis is established by histological assessment. However, this can present conflicts in grading gliomas, which justifies new tools to assist the pathologist in his analysis. Currently, it is known that there are changes in glycosylation pattern of molecules associated with cancer, and the discovery of the ability of lectins to recognize these changes made these tools applicable for biomedical diagnosis. Thus, the aim of this study is to analyze the labelling of C6 and astrocyte lineage cells with fluorescent lectins CpL, WGA and Con A. Methods: The cells were cultured under sterile conditions at 37°C in an atmosphere with 5% CO2 until they reached confluence. They were then washed with PBS and labeled with CpL, WGA, or Con A lectins in a concentration of 1 mg/ml. Negative controls were incubated with the carbohydrate that competitively inhibits the reaction (D-galactose, β-N-acetylglucosamine and glucose, respectively), at a concentration of 0.1 M. The incubation occurred for one hour with protection from the light, the analysis was performed on a fluorescence microscope. For flow cytometry quantitation, cells were labeled following the same previous protocol, except that the incubation time was 15 minutes. Subsequently, the cells were washed, centrifuged, transferred to tubes and resuspended in PBS to carry out the reading on a cytometer. Results: The CpL lectin better labeled astrocytes. However, it showed a poor performance compared to other lectins. On the other hand, the WGA lectin efficiently marked both astrocytes and C6 cells; the latter presented the double emission compared to the former. Thus, it is possible to infer that the CpL and WGA lectins are not able to recognize important differences in the glycosylation profile in the membranes of C6 cells and astrocytes. However, the lectin Con A efficiently marked C6 cells, defining their morphology and showing that there is a nearly uniform distribution of glucose along the surface of the membrane, which was not observed in astrocytes. This also exhibited a median fluorescence about 99 times greater than that obtained for astrocytes. Thus, Con A showed to be a marker capable of differentiate cells of murine glioma lineage from primary astrocytes. Conclusion: Based on these results we can infer that the Con A lectin may be a tool for a more efficient identification of glioma cells in histopathological analysis.
APA, Harvard, Vancouver, ISO, and other styles
5

Roller, Benjamin Thomas. "A nanoencapsulated visible dye for intraoperative delineation of brain tumor margins." Thesis, Georgia Institute of Technology, 2011. http://hdl.handle.net/1853/42805.

Full text
Abstract:
Brain and central nervous cancer presents a significant clinical burden, accounting for 2.4% of all cancer deaths. High grade glioma is particularly deadly, with 5 year survival times of 35% or less. Traditional treatment includes tumor resection followed by radiation therapy or chemotherapy. Aggressive resection is essential in order to prolong patient life. In fact, several studies have shown that life expectancy increases with increased extent of resection. Extent of resection is burdened by the fact that surgeons must be careful not to remove functional brain tissue. Resection is incomplete more often than not due to lack of visual cues for the surgeon. He must rely on tactile sensation to distinguish tumor from healthy tissue. Methods such as intraoperative MRI and CT exist, but these require expensive equipment and special training that is not available in all surgical environments. Some laboratories have proposed small molecule dyes to solve this problem, but these are insufficient when used in an invasive tumor model. It was the goal of this research to provide an objective cue in the form of a nanoencapsulated visible dye without the need for additional equipment of changes to the surgery process itself other than injection of the dye. We hypothesized that the nanocarrier would allow staining of the tumor through passive targeting by taking advantage of the enhanced permeability and retention effect. Once the nanocarriers have reached the desired target, they would not diffuse out into healthy tissue due to their large size compared to small molecule dyes, which readily diffuse out and stain healthy tissue. To test this hypothesis, we prepared and characterized a liposomal nanocarrier encapsulating Evans blue dye. The nanocarrier was tested for safety in vitro and in vivo, then used to delineate tumor margins in an invasive rat glioma model in vivo. Microscopic analysis was then conducted to ensure only tumor tissue was stained by the nanocarrier. This thesis presents a successful method of tumor border delineation to provide surgeons with positive visual cues without the need for changes in surgical environment or techniques.
APA, Harvard, Vancouver, ISO, and other styles
6

Shirahata, Mitsuaki. "Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis." Kyoto University, 2008. http://hdl.handle.net/2433/124241.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Manita, Muftah. "The prognostic value of perfusion MRI in cerebral glioma." Thesis, University of Nottingham, 2012. http://eprints.nottingham.ac.uk/12776/.

Full text
Abstract:
Introduction Cerebral glioma is the most prevalent primary brain tumour, of which the majority are high grade gliomas. High grade gliomas possess a poor prognosis, and glioblastoma patients survive less than one year after diagnosis. To date, histological grading is used as the standard technique for diagnosis and survival prediction. Previous studies using advanced techniques such as MR Perfusion have achieved a high sensitivity but a low specificity in identifying high grade gliomas. Moreover, they have failed to distinguish glioblastoma from anaplastic glioma. The purpose of the study presented here is to assess the diagnostic and prognostic value for cerebral glioma of cerebral blood volume maps derived from MR perfusion. Methods This retrospective study was approved by the local research ethics committee and clinical audit office. This study included 123 patients with newly diagnosed cerebral glioma, of all grades. Histological diagnosis was used as the standard reference for all potential patients. The relative tumour blood volume (rTBVmax) derived from MR perfusion was used for radiological grading of cerebral glioma. Receiver operating characteristics (ROC) were used to define the best threshold value in distinguishing the glioma grades and in determining the accuracy values (sensitivity, specificity, and positive and negative predictive values). For survival analysis, Kaplan-Meier was used to illustrate and compare the discriminatory value of the histological and radiological classifications. A multiple Cox regression model was used to assess the prognostic value of both classifications in addition to other tested demographic and clinical variables. Finally, the influence of potential moderators was assessed using ANOVA, to assess whether the variation in rTBVmax was only due to the difference in tumour grades. Results A model data set (n = 50) produced a 7-fold increase of TBVmax in tumour versus white matter and provided sensitivity and specificity of 97% and 94%, respectively, in distinguishing high versus low grade glioma. Moreover, a threshold value of 9.6 provided sensitivity and specificity of 100% and 56% in differentiating glioblastoma within the group of high grade gliomas. These threshold values were applied to the second group (n = 73) and provided sensitivity and specificity of 96% and 95% in distinguishing high versus low grade glioma, and 97% and 73% in differentiating, within the high grade gliomas, glioblastoma from anaplastic glioma. Using these two thresholds for a three-tier radiological classification, both the Kaplan-Meier plots and the multiple Cox regression showed that radiological classification was the most independent predictor of survival and tumour progression. The proposed radiological classification system was better than histological classification in predicting glioma patients survival especially noted in a group of moderately hyperaemic rTBVmax. Conclusion MR perfusion is a non-invasive and robust technique in glioma grading and survival prediction. The diagnostic value of rTBVmax derived from MR perfusion in differentiating high versus low grade glioma is promising. It may have a role in the future in defining the appropriate treatment. However, the proposed radiological classification was inferior in differentiating anaplastic glioma from glioblastoma multiforme. In the future, a more advanced multimodal MR, such as MR spectroscopy and MR diffusion, may be studied, besides MR perfusion, in order to improve this diagnostic accuracy.
APA, Harvard, Vancouver, ISO, and other styles
8

Ciezka, Magdalena. "Improvement of Protocols for Brain Cancer Diagnosis and Therapy Response Monitoring Using Magnetic Resonance Based Molecular Imaging Strategies." Doctoral thesis, Universitat Autònoma de Barcelona, 2015. http://hdl.handle.net/10803/666281.

Full text
Abstract:
Los tumores cerebrales constituyen menos del 2% de los tumores primarios, pero son uno de los peores tipos de cáncer en cuanto a “años de vida perdidos”. Los gliomas son los tumores cerebrales más prevalentes, con una esperanza de vida inferior a 15 meses para los casos de alto grado, como los glioblastomas (GBM). El método no invasivo más utlilizado para diagnóstico y seguimiento de la respuesta a la terapia en tumores cerebrales es la Resonancia Magnética (MR), en forma de imagen (MRI) y espectroscopía (MRS) o imagen espectroscópica (MRSI). Sin embargo, debido a restricciones éticas relacionadas a la participación de pacientes humanos en investigación, la optimización de los métodos de diagnóstico y seguimiento de la terapia requieren modelos preclínicos que reproduzcan las patologías humanas. Para este tipo de estudios, se utilizan principalmente modelos murinos, que pueden dividirse en modelos genéticamente modificados (GEM) con desarrollo espontáneo de tumor y los modelos de generación de tumores por inyección estereotáxica de líneas celulares. En la presente tesis, se llevó a cabo una detallada caracterización de dos colonias GEM, S100β-v-erbB/inK4a-Arf (+/-) y GFAP-V12 HA-ras B8. Se observó una baja penetrancia de desarrollo de tumores (16% y 1% respectivamente), haciendo de éstos una herramienta poco útil para estudios de respuesta a la terapia. La escasez de modelos preclínicos de grado bajo/intermedio sirvió de motivación para desarrollar un modelo de tumor glial transplantable con esas características, por disgregación de tumores provenientes de la colonia GEM. Ello nos debería permitir obtener una mayor incidencia tumoral en comparación con las colonias GEM. Se generaron gliosferas a partir de tumores GEM de grado III y se logró más de un 60% de penetrancia cuando estas células fueron inyectadas estereotácticamente en el estriado de ratones C57BL/6. Sin embargo, la aplicación de protocolos de descongelación y cultivo a éstas células ocasionó una progresión a grado IV (GBM), lo que sugiere que el modelo generado constituye, potencialmente, un modelo murino de GBM secundario. Además, este modelo transplantable fue ampliamente caracterizado por métodos de MRI/MRSI, así como por métodos de perturbación del patrón espectral con MRSI (PE-MRSI) para una posible aplicación en el desarrollo de clasificadores de respuesta a la terapia en tumores. También se llevó a cabo una evaluación genética restringida de los modelos murinos seleccionados (p.e. tumores GL261, línea celular GL261, GEM y tumores derivados de GEM), utilizando el método de secuenciación de Sanger para comprobar la presencia de mutaciones normalmente presentes en gliomas (en los genes IDH1, IDH2 y p53). Finalmente, esta tesis describe la estrategia desarrollada para estudios longitudinales de detección de respuesta temprana a la terapia/recidiva en tumores preclínicos, utilizando métodos de imagen molecular basados en MRSI. Así ratones implantados con tumores GL261 (glioblastoma) recibieron tratamiento con temozolamida (TMZ), basándonos en protocolos previamente establecidos. La detención del crecimiento tumoral (respuesta a la terapia) fue detectada por MRI. Tanto animales tratados como animales control fueron estudiados por MRSI y técnicas de reconocimiento de patrones (extracción de fuentes en sistema semi-supervisado). Las fuentes extraídas de regiones de interés fueron capaces de distinguir entre tumores GL261 proliferando activamente y tumores respondiendo a la terapia, basándose en cambios de patrón del metaboloma registrado por MRSI. Se obtuvieron mapas nosológicos codificados en tipo e intensidad de color durante y después de la terapia, lo que permitió un seguimiento de la respuesta, así como la detección de heterogeneidad intratumoral en dicha respuesta, siendo capaces de detectar la detención del crecimiento tumoral y la recidiva antes de los cambios observados en el volumen tumoral por MRI. Esta metodología fue ratificada por análisis histopatológico y cálculo de tasas de proliferación, apoptosis y de índice mitótico.
Brain tumours account for less than 2% of all primary tumours, but are one of the most lethal cancers when “life lost” years are considered. Gliomas are the most prevalent type with a median life expectancy below 15 months for the high grade ones, such as glioblastomas (GBM). The most common non-invasive medical technique used for tumour diagnosis and therapy monitoring of brain tumours patients is Magnetic Resonance (MR), in the form of imaging (MRI) and spectroscopy (MRS) or spectroscopic imaging (MRSI). However, due to the ethical restrictions regarding the use of human patients for research study, the improvement of diagnostic and therapy follow-up protocols requires reliable models that mimic human disease. In this regard, mainly murine models are used and can be divided into the genetically engineered model (GEM) of spontaneous tumour development and the engrafted tumour model. In this thesis, a comprehensive MR characterization of two GEM colonies, namely S100β-v-erbB / inK4a-Arf (+/-) and GFAP-V12 HA-ras B8, was carried out. A low tumour penetrance found (16% and 1%, respectively) together with stochastic onset of GEM tumours, made them impractical for use in therapy response studies. The latter and the scarcity of low/intermediate grade brain tumour preclinical models motivated us to attempt to develop a transplantable glial tumour model of low/intermediate grade by disaggregation of a tumour mass from GEM. This should allow us to obtain an increased tumour incidence rate in comparison to GEM animals. Gliospheres from a grade III GEM tumour were successfully generated and displayed more than 60% penetrance, when stereotactically injected into the striatum of C57BL/6 mice. However, the application of freezing and cell culture protocols produced a progression to grade IV GBM, which made the developed transplantable model qualify as potential secondary GBM model in mice. Additionally, this transplantable model was widely characterized using MRI/MRS methods, as well as perturbation-enhanced MRSI (PE-MRSI) for a possible application in the future in therapy strategies and development of tumour therapy response detection classifiers. A restricted genetic evaluation of selected murine tumour models (i.e. GL261 tumours, GL261 cell line, GEM and GEM-derived tumours) was carried out using the Sanger method to check for a possible presence of particular driver mutations commonly occurring in gliomas (IDH1, IDH2 and p53). Finally, the work describes the strategy followed for longitudinal therapy studies follow-up and early response/relapse detection in preclinical brain tumours, through molecular imaging methods based in MRSI. GL261 (glioblastoma) tumour bearing mice were treated with temozolomide (TMZ), based on previously established protocols. The expected transient growth arrest (response to therapy) was detected by MRI. Animals subjected to therapy and control animals were followed up by MRSI and pattern recognition techniques (semi-supervised source extraction) were applied. The sources extracted from the region of interest were able to discriminate between GL261 tumours actively proliferating and tumours responding to therapy, based on their metabolome pattern changes recorded by MRSI. Colour-coded nosological images produced throughout and after the course of therapy allowed convenient tracking of response changes and differentiated the intratumoural heterogeneity of response, hinting the growth arrest and relapse, before changes in tumour volume were observed by MRI. The methodology was validated with histopathological analysis and calculation of proliferation and apoptotic rates and mitotic index.
APA, Harvard, Vancouver, ISO, and other styles
9

Billard, Pauline. "Maintenance télomérique : intérêt dans le diagnostic des gliomes en lien avec le métabolisme mitochondrial." Thesis, Lyon, 2021. http://www.theses.fr/2021LYSE1303.

Full text
Abstract:
Le complexe Shelterin, composé de 6 protéines (POT1 / TRF1 / TRF2 / TIN2 / RAP1 et ACD) joue un rôle majeur au niveau des télomères. Ainsi, il permet la protection de l’extrémité simple brin par la formation de la D-loop, la régulation de la signalisation des voies de dommages à l’ADN ; il participe à la réplication des télomères et contrôle l’accessibilité et la processivité de la télomérase, unique enzyme permettant l’allongement des télomères. Au cours de cette thèse, mon travail s’est organisé autour de 2 principaux axes, le premier, fondamental s’est intéressé aux effets extra-télomériques de la protéine ACD (anciennement appelée TPP1). Le deuxième, plus transversal s’est attardé sur les processus de maintenance des télomères dans le cas des gliomes. Concernant le premier aspect, il est maintenant connu que la protéine ACD fait le lien entre TIN2 et TERT (sous unité catalytique de la télomérase) aux télomères. Ces deux protéines peuvent aussi partiellement se localiser à la mitochondrie et y possèdent alors divers effets sur le métabolisme, la régulation du stress oxydant ou encore la mitophagie. Ainsi, et suite à des prédictions in silico de potentiel MTS pour ACD, nous avons émis l’hypothèse qu’ACD pourrait être le partenaire manquant de TIN2 et TERT à la mitochondrie. Dans ce cas il restait alors à identifier ses fonctions mitochondriales. Après avoir démontré la localisation partielle d’ACD à la mitochondrie par différentes méthodes, nous avons pu mettre en évidence son influence dans la protection contre le stress oxydatif. Ainsi la surexpression d’ACD réduit la production secondaire de radicaux oxygénés mitochondriaux et la perte d’ADN mitochondrial. Le stress oxydatif causant la réduction des foci mitochondriaux d’ACD. Dans un second temps, nous nous sommes intéressés aux mécanismes de maintenance des télomères (TMM) que les cellules cancéreuses acquièrent afin d’outrepasser la sénescence réplicative. Dans ce sens, les tumeurs peuvent réactiver la télomérase (95% des cas) ou utiliser un processus alternatif (ALT) basé sur la recombinaison homologue (5% des cas). Pour les gliomes, jusqu’à 25% des tumeurs utilisent le processus ALT, associé à la perte d’ATRX, les autres gliomes utilisent la télomérase et présentent classiquement une mutation du promoteur de TERT (TERTmt). Ces deux marqueurs moléculaires ont par ailleurs une valeur diagnostique et pronostique et font parties des critères de classification histo-moléculaire de l’OMS . Or, de 4 à 28% des gliomes (selon les sous-types) ne possèdent ni altération d’ATRX ni mutation de TERT suggérant une activation de l’un des TMM par d’autres altérations voire d’autres voies. Dans ce sens, nous avons développé un test mesurant le TMM vrai en nous basant sur la recherche des c-circle (un marqueur du ALT) et proposé un algorithme breveté (TeloDiag) prenant en compte ce TMM, les mutations d’IDH et le grading histologique. Le TeloDiag permet de re-classer 38% des gliomes atypiques (au niveau moléculaire). Il a généré une nouvelle catégorie de tumeurs de haut grade IDHwt et ALT+, n’existant pas dans la classification OMS et montrant une tendance à un meilleur pronostic que les glioblastomes IDHwt (TERTmt). Enfin, nous avons apporté la preuve de concept de la faisabilité de ce test en circulant, pour les astrocytomes IDHmt
The Shelterin complex, made of 6 proteins (POT1 / TRF1 / TRF2 / TIN2 / RAP1 and ACD) plays a major role in telomeres. Thus, it allows the protection of the telomeric single-stranded end by the formation of the D-loop, the regulation of DNA damage signaling pathways; it participates in telomere replication and controls the accessibility and processivity of the telomerase, the unique enzyme allowing telomere lengthening. During this thesis, my work was organized in 2 main axes, the first, fundamental, was interested in the extra-telomeric effects of the ACD protein (also called TPP1). The second, more transversal, focused on the processes of telomere maintenance in gliomas. Concerning the first aspect, it is now known that the ACD protein makes the link between TIN2 and TERT (catalytic subunit of telomerase) in the telomeres. These two proteins can also partially localize to the mitochondria and then have various effects on mitochondrial metabolism, on the oxidative stress regulation or on the mitophagy process. Thus, and following in silico predictions of a putative MTS for ACD, we hypothesized that ACD could be the missing partner of TIN2 and TERT in the mitochondria. In this case, it then remained to identify its mitochondrial functions. After demonstrating the partial localization of ACD in the mitochondria by different methods, we were able to demonstrate its influence in the protection against oxidative stress. Thus overexpression of ACD reduces secondary production of mitochondrial oxygen radicals and loss of mitochondrial DNA. Oxidative stress causing reduction of ACD mitochondrial foci. Secondly, we looked at the telomere maintenance mechanisms (TMM) that cancer cells acquire in order to override replicative senescence. In this sense, tumors can reactivate telomerase (95% of cancer) or use an alternative process (ALT) based on homologous recombination (5% of cancer). In the case of gliomas, up to 25% of tumors use the ALT process, associated with the loss of ATRX, the other gliomas use telomerase and typically have a mutation of the TERT promoter (TERTmt). These two molecular markers also have diagnostic and prognostic value and are part of the WHO histo-molecular classification criteria. But, 4 to 28% of gliomas (depending on the subtypes) do not have an ATRX alteration or TERT mutation suggesting activation of one of the TMM by other alterations or even other pathways. In this sense, we have developed a test measuring the true TMM based on the detection of c-circles (a marker of ALT) and proposed a patented algorithm (TeloDiag) taking into account this TMM, IDH mutations and the histological grading. The TeloDiag makes it possible to re-classify 38% of atypical gliomas (at the molecular level). It generated a new category of high grade IDHwt and ALT + tumors, not found in the WHO classification and showing a tendency for a better prognosis than IDHwt glioblastomas (TERTmt). Finally, we provided the proof of concept of the feasibility of this circulating test for IDHmt astrocytomas
APA, Harvard, Vancouver, ISO, and other styles
10

Taylor, G. Scott. "Design and Development of Oligonucleotide Microarrays and their Application in Diagnostic and Prognostic Estimation of Human Gliomas." VCU Scholars Compass, 2006. http://scholarscompass.vcu.edu/etd/1459.

Full text
Abstract:
DNA microarrays represent an ultra-high throughput gene expression assay employed to study the transcriptomic profiles of biological tissues. These devices are increasingly being used to study many aspects of gene regulation, and there is growing interest in the biotechnology and pharmaceutical industries for developing such devices in efforts toward rational product/drug design. The DNA microarray also provides a unique and objective means for diagnosis and prognosis of human diseases based on patterns of gene expression. This is especially important in cancer research and the thrust toward personalized medicine. This dissertation details the design and development of oligonucleotide microarrays and the design and execution of a gene expression study conducted using human glioma specimines. Chapter 2 details the design and development a ~10,000 gene human oligonucleotide microarray. This device consisted of a 21,168 features, each composed of a particular human gene-probe and was applied to the challenge of diagnostic and prognostic estimation for human gliomas (chapter 3). Gliomas are the most frequent and deadly neoplasms of the human brain characterized by a high misdiagnosis rate and low survival. The study in chapter 3 demonstrated that the specified design and development parameters were appropriate for conducting gene expression analysis and that this platform can be used successfully to predict malignancy grade and survival for glioma patients.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Glioma diagnosis"

1

Gliomas. Berlin: Springer, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

P, Rock Jack, ed. The practical management of low-grade primary brain tumors. Philadelphia: Lippincott Williams & Wilkins, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Scarabino, Tommaso. Imaging Gliomas After Treatment: A Case-based Atlas. Milano: Springer Milan, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Glioma. Springer Verlag, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Karim, Abul Bashr Mohammed Fazlul. and Laws Edward R, eds. Glioma: Principles and practice in neuro-oncology. Berlin: Springer-Verlag, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Barnett, Gene H. High-grade Gliomas: Diagnosis and Treatment. Humana P.,U.S., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Barnett, Gene H. High-Grade Gliomas: Diagnosis and Treatment (Current Clinical Oncology). Humana Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

H, Barnett Gene, ed. High-grade gliomas: Diagnosis and treatment. Totowa, N.J: Humana Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

High-Grade Gliomas: Diagnosis and Treatment. Humana, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Friedman, Allan H., Roger E. McLendon, Darell D. Bigner, John H. Sampson, and Henry S. Friedman. Duke Glioma Handbook: Pathology, Diagnosis, and Management. Cambridge University Press, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Glioma diagnosis"

1

Stam, F. C. "The Problems of Pathological Diagnosis." In Glioma, 17–36. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-84127-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nasrallah, MacLean P. "Glioma Diagnosis and Classification: Illuminating the Gold Standard." In Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries, 3–10. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72084-1_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Li, Yuexiang, and Linlin Shen. "Deep Learning Based Multimodal Brain Tumor Diagnosis." In Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries, 149–58. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-75238-9_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kawai, Nobuyuki, Yoshihiro Nishiyama, and Takashi Tamiya. "Newly Diagnosed Glioma: Diagnosis Using Positron Emission Tomography with Methionine and Fluorothymidine." In Tumors of the Central Nervous System, Volume 2, 103–12. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-0618-7_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Westermark, B., M. Nistér, and C. H. Heldin. "Oncogenes, Growth Factors and the Pathogenesis of Human Glioma: The 1986 Engelhardt Lecture." In Brain Oncology Biology, diagnosis and therapy, 7–13. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3347-7_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Nakamura, Osamu, and Masao Iwamori. "Glycolipid in Human Glioma: Detection with Specific Antibodies and Its Application for Diagnosis of Gliomas." In Biological Aspects of Brain Tumors, 421–24. Tokyo: Springer Japan, 1991. http://dx.doi.org/10.1007/978-4-431-68150-2_59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bradford, R., J. L. Darling, and D. G. T. Thomas. "Heterogeneity in Chemosensitivity and Acquisition of Drug Resistance in a Murine Model of Glioma." In Brain Oncology Biology, diagnosis and therapy, 363–67. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3347-7_65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yin, Baocai, Hu Cheng, Fengyan Wang, and Zengfu Wang. "CA-Net: Collaborative Attention Network for Multi-modal Diagnosis of Gliomas." In Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries, 52–62. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08999-2_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bateman, D. E., J. R. McDermott, D. Hughes, and J. A. Edwardson. "The Selective Release of Polypeptides from Human Glioma Cell Cultures and their Modification by Dexamethasone." In Brain Oncology Biology, diagnosis and therapy, 143–48. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3347-7_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Albert, Nathalie L., Bogdana Suchorska, Adrien Holzgreve, and Marcus Unterrainer. "Case 25: Primary Diagnosis of an Isocitrate Dehydrogenase (IDH) Wild-Type Glioma." In Clinical Nuclear Medicine in Neurology, 125–28. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-83598-9_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Glioma diagnosis"

1

Shboul, Zeina, and Khan Iftekharuddin. "Prediction of low-grade glioma progression using MR imaging." In Computer-Aided Diagnosis, edited by Horst K. Hahn and Kensaku Mori. SPIE, 2019. http://dx.doi.org/10.1117/12.2512620.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gates, Evan, Jonathan Lin, Jeffrey S. Weinberg, Sujit S. Prabhu, Jackson Hamilton, John D. Hazle, Gregory N. Fuller, Veera Baladandayuthapani, David Fuentes, and Dawid Schellingerhout. "Advanced magnetic resonance imaging based algorithm for local grading of glioma." In Computer-Aided Diagnosis, edited by Horst K. Hahn and Maciej A. Mazurowski. SPIE, 2020. http://dx.doi.org/10.1117/12.2549607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Juarez Chambi, Ronald, Carmen Kut, Kaisorn L. Chaichana, Alfredo Quiñones-Hinojosa, Xingde Li, and Javier Jo. "Neural networks for in situ detection of glioma infiltration using optical coherence tomography." In Computer-Aided Diagnosis, edited by Horst K. Hahn and Maciej A. Mazurowski. SPIE, 2020. http://dx.doi.org/10.1117/12.2549612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Korfiatis, Panagiotis, Timothy L. Kline, and Bradley J. Erickson. "Evaluation of a deep learning architecture for MR imaging prediction of ATRX in glioma patients." In Computer-Aided Diagnosis, edited by Kensaku Mori and Nicholas Petrick. SPIE, 2018. http://dx.doi.org/10.1117/12.2293538.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shi, Hong-yan, Xiao-qiang Wu, Li-hua Wang, and Li Li. "Study on MRI and CT Combined Diagnosis Technology Application in Brain Glioma Diagnosis." In 2017 7th International Conference on Applied Science, Engineering and Technology (ICASET 2017). Paris, France: Atlantis Press, 2017. http://dx.doi.org/10.2991/icaset-17.2017.15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhou, Yan, Binlin Wu, Cheng-hui Liu, Xinguang Yu, Gangge Cheng, Kai Wang, Chunyuan Zhang, Lingyan Shi, and Robert R. Alfano. "Diagnosis of glioma brain cancer using visible resonance Raman spectroscopy." In Frontiers in Optics. Washington, D.C.: OSA, 2018. http://dx.doi.org/10.1364/fio.2018.jw4a.3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zhou, Yan, Cheng-Hui Liu, Ke Zhu, Binlin Wu, Xinguang Yu, Gangge Cheng, Mingyue Zhao, et al. "Human brain glioma grading using label free laser-induced fluorescence spectroscopy." In Optical Biopsy XVII: Toward Real-Time Spectroscopic Imaging and Diagnosis, edited by Robert R. Alfano, Stavros G. Demos, and Angela B. Seddon. SPIE, 2019. http://dx.doi.org/10.1117/12.2511687.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Palande, V., D. Raviv-Shay, and M. Frenkel-Morgenstern. "PO-301 Diagnosis of glioma tumours using circulating cell-free DNA." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Njeh, Ines, Lamia Sallemi, Mohamed Ben Slima, Ahmed Ben Hamida, Stephane Lehericy, and Damien Galanaud. "A computer aided diagnosis ‘CAD’ for brain glioma exploration." In 2014 International Conference on Advanced Technologies for Signal and Image Processing (ATSIP). IEEE, 2014. http://dx.doi.org/10.1109/atsip.2014.6834615.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Amaya-Rodriguez, I., L. Duran-Lopez, F. Luna-Perejon, J. Civit-Masot, J. Dominguez-Morales, S. Vicente, A. Civit, D. Cascado, and A. Linares-Barranco. "Glioma Diagnosis Aid through CNNs and Fuzzy-C Means for MRI." In 11th International Conference on Neural Computation Theory and Applications. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0008494005280535.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Glioma diagnosis"

1

Zhang, Hui-Mei, Xiao-Bing Huo, Hua-Long Wang, and Chen Wang. Recurrent glioma and radiation necrosis: a meta-analysis of MRI diagnosis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Qian, Yuhua Hu, Haihua Zhan, and Yawei He. The diagnostic value of miR-221/222 in glioma : a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2021. http://dx.doi.org/10.37766/inplasy2021.3.0064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hua, Rong, Yi-Bing Shi, Yu-Fei Fu, and Chen Wang. Diagnostic performance of dynamic susceptibility contrast-enhanced perfusion-weighted imaging in differentiating recurrence from radiation injury in postoperative glioma: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Huo, Zhenyu, Feifei Chong, Lingyu Yin, Zongliang Lu, Jie Liu, and Hongxia Xu. Accuracy of the GLIM criteria for diagnosing malnutrition: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Glioma diagnosis' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography